Sodium-glucose cotransporter 2 inhibitors and renal cancer in the US FDA adverse event reporting system.
美國 FDA 不良事件報告系統中鈉-葡萄糖共轉運蛋白 2 抑制劑與腎癌的關聯。
Eur J Clin Pharmacol 2024-09-16
Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease.
非酒精性脂肪肝病/代謝功能障礙相關脂肪肝病的新藥治療管道。
J Clin Transl Hepatol 2024-09-16
Synergistically improved cardiovascular outcomes in type 2 diabetes mellitus patients with combined treatment of SGLT-2 inhibitors and pioglitazone.
SGLT-2 抑制劑與 pioglitazone 聯合治療對 2 型糖尿病患者心血管結果的協同改善。
Front Endocrinol (Lausanne) 2024-09-16
Effects of canagliflozin on kidney oxygenation evaluated using blood oxygenation level-dependent MRI in patients with type 2 diabetes.
canagliflozin 對於 2 型糖尿病患者腎臟氧合的影響，使用血氧水平依賴性 MRI 進行評估。
Front Endocrinol (Lausanne) 2024-09-16
O-linked β-N-acetylglucosamine (O-GlcNAc) modification: Emerging pathogenesis and a therapeutic target of diabetic nephropathy.
O-GlcNAc 修飾：糖尿病腎病的新興發病機制及治療靶點。
Diabet Med 2024-09-16
Role of oral hypoglycaemic drugs in preventing complication in non-alcoholic fatty liver disease with type 2 diabetes mellitus.
口服降血糖藥物在預防2型糖尿病合併非酒精性脂肪肝疾病併發症中的作用。
J Pak Med Assoc 2024-09-16
Early Clinical Experience of Finerenone in People with Chronic Kidney Disease and Type 2 Diabetes in Japan-A Multi-Cohort Study from the FOUNTAIN (FinerenOne mUltidatabase NeTwork for Evidence generAtIoN) Platform.
日本慢性腎病與2型糖尿病患者中Finerenone的早期臨床經驗—來自FOUNTAIN（FinerenOne多數據庫網絡證據生成）平台的多隊列研究。
J Clin Med 2024-09-14
Tree-based scan statistics to generate drug repurposing hypotheses: a test case using sodium-glucose cotransporter-2 inhibitors.
基於樹狀掃描統計生成藥物重定位假說：以鈉-葡萄糖共轉運蛋白-2 抑制劑為例。
Am J Epidemiol 2024-09-13